Literature DB >> 2861892

A phosphoglycoprotein associated with taxol resistance in J774.2 cells.

S N Roy, S B Horwitz.   

Abstract

Taxol is an inhibitor of cell replication that promotes the assembly of microtubules in vitro and in cells. In the murine macrophage-like cell line J774.2, a taxol-resistant subline (J7/TAX-50) has been developed in vitro by growing the cells in increasing drug concentrations. These cells, which are approximately 800-fold resistant to taxol, display some cross-resistance to colchicine, vinblastine, puromycin, doxorubicin, and actinomycin D but remain sensitive to bleomycin. Binding of radiolabeled drug to the resistant cells is reduced by approximately 90%. Resistant cells grown in the absence of drug for 10 days (J7/TAX-0D10), 1 month (J7/TAX-0D30), and 8 months (J7/TAX-0D240) regain a major portion (27, 92, and 99%, respectively) of their sensitivity to the drug. However, binding of the drug to the J7/TAX-0D30 and J7/TAX-0D240 cells is increased to only 20 and 70%, respectively, of that measured with sensitive cells. Analysis of plasma membranes by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by silver staining reveals the presence of a prominent protein with an approximate molecular weight of 135,000 in the resistant line that is essentially absent from the parental line and from both of the J7/TAX-0D30 and J7/TAX-0D240 lines. Although this protein can be seen in J7/TAX-0D10, its quantity is diminished. The Mr 135,000 protein is also observed in the resistant cells when they are labeled with [3H]leucine, [35S]methionine, [3H]glucosamine, or [32P]orthophosphate. Plasma membranes from colchicine- or vinblastine-resistant J774.2 cells also contain prominent phosphoglycoproteins, with approximate molecular weights of 145,000 and 150,000, respectively. Partial purification of the Mr 135,000 glycoprotein by agarose-bound ricinus communis agglutinin I-agarose affinity chromatography indicates that it accounts for approximately 4 to 5% of total membrane protein. A Mr 100,000 phosphoglycoprotein, present in the membranes of J774.2 cells is essentially absent in J7/TAX-50 cells after labeling with [3H]glucosamine or [32P]orthophosphate. Phosphoamino acid analysis of the Mr 135,000 and 100,000 phosphoglycoproteins reveals that the phosphorylation sites are serine and threonine residues. There appears to be a good correlation between the presence of the Mr 135,000 phosphoglycoprotein in plasma membranes and resistance to taxol.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861892

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.

Authors:  M Kavallaris; D Y Kuo; C A Burkhart; D L Regl; M D Norris; M Haber; S B Horwitz
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 2.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  The extended-MDR phenotype.

Authors:  R Davey; M Davey
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

4.  Paclitaxel-2'-Ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity.

Authors:  Tadatoshi Tanino; Akihiro Nawa; Eisaku Kondo; Fumitaka Kikkawa; Tohru Daikoku; Tatsuya Tsurumi; Chenhong Luo; Yukihiro Nishiyama; Yuki Takayanagi; Katuhiko Nishimori; Seiji Ichida; Tetsuyuki Wada; Yasuyoshi Miki; Masahiro Iwaki
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

5.  Differential effect of taxol in rat primary and metastatic prostate tumors: site-dependent pharmacodynamics.

Authors:  W C Yen; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

Review 6.  New microtubular agents in pediatric oncology.

Authors:  N L Seibel; G H Reaman
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 7.  Effects of phosphorylation of P-glycoprotein on multidrug resistance.

Authors:  U A Germann; T C Chambers; S V Ambudkar; I Pastan; M M Gottesman
Journal:  J Bioenerg Biomembr       Date:  1995-02       Impact factor: 2.945

Review 8.  Molecular analysis of the multidrug transporter.

Authors:  U A Germann
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 9.  A preliminary risk-benefit assessment of paclitaxel.

Authors:  R J Bitton; W D Figg; E Reed
Journal:  Drug Saf       Date:  1995-03       Impact factor: 5.606

10.  Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.

Authors:  L R Kelland; G Abel
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.